FSHR rs121912529: Reproductive Health and Variant Insights
The genetic variant rs121912529 is an ultra-rare missense change located in the follicle-stimulating hormone receptor (FSHR) gene. It causes a loss of function in the FSH receptor, disrupting normal ovarian response to pituitary hormone signaling. In medical literature, homozygous or compound heterozygous inheritance of this variant is associated with hypergonadotropic hypogonadism, primary ovarian insufficiency, and ovarian dysgenesis.
What each genotype means
Typical FSH receptor function
This is the most common genotype, representing the reference sequence at this position. Individuals with this genotype do not carry the pathogenic loss-of-function variant that is linked to hereditary hypergonadotropic ovarian dysgenesis.
This is the predominant genotype in all global populations.
Unaffected carrier status
As a carrier of this variant, you possess one copy of the normal FSHR gene and one copy containing the pathogenic mutation. Because this condition is typically inherited in an autosomal recessive manner, carriers generally do not exhibit the clinical features of ovarian dysgenesis; however, they may be at risk of passing the variant to their offspring.
This genotype is extremely rare and is generally only identified in specific families or populations where the variant has been historically reported.
Possible ovarian dysgenesis
This genotype indicates that both copies of the FSHR gene contain the loss-of-function mutation. Research indicates this specific mutation impairs the follicle-stimulating hormone receptor's ability to signal correctly, which is associated with hypergonadotropic ovarian dysgenesis, primary amenorrhea, and lack of spontaneous pubertal development. Please discuss these findings with a qualified healthcare provider or genetic counselor for clinical context and implications.
This genotype is ultra-rare and is found almost exclusively in individuals with a specific clinical diagnosis of ovarian dysgenesis, often in families with a history of the condition.
What Is rs121912529 and Where Is It Located?
The variant rs121912529 represents a single-nucleotide alteration within the FSHR gene, located on chromosome 2. This variant introduces an amino acid substitution—historically documented in foundational endocrine genetics as an alanine-to-valine change (p.Ala189Val)—within the extracellular ligand-binding domain of the receptor. Under standard nomenclature, the reference allele encodes the functional receptor, whereas the alternate allele disrupts standard protein folding and transport to the cell surface. Because the cellular machinery fails to properly express the receptor at the plasma membrane, target tissues become largely unresponsive to circulating follicle-stimulating hormone. Unlike common non-coding polymorphisms, rs121912529 directly alters the primary structure of the protein, categorizing it as a classic loss-of-function missense mutation.
The Biological Role of the FSHR Gene
The FSHR gene provides instructions for producing the follicle-stimulating hormone receptor, a member of the G-protein coupled receptor family. In females, this receptor is predominantly expressed on ovarian granulosa cells, where it binds follicle-stimulating hormone (FSH) released by the anterior pituitary. Normal binding stimulates intracellular cyclic AMP (cAMP) production, initiating downstream cascades such as the PI3K-AKT and ERK signaling pathways. These signals govern ovarian follicle maturation, estrogen synthesis, and normal menstrual cycling. In males, the receptor is expressed in testicular Sertoli cells, where it contributes to the regulation of spermatogenesis. When receptor signaling is impaired or absent, gonadal development and gametogenesis stall despite elevated pituitary gonadotropin release.
Clinical Significance and Evidence Strength
The clinical evidence linking rs121912529 to hypergonadotropic hypogonadism and ovarian dysgenesis type 1 is classified as moderate to strong in established endocrine literature. Originally identified in Finnish families presenting with primary amenorrhea and underdeveloped secondary sexual characteristics, this variant follows an autosomal recessive inheritance pattern. Individuals carrying two loss-of-function alleles typically present with elevated serum FSH and luteinizing hormone (LH) paired with deficient estrogen, a condition often described as resistant ovary syndrome or hypergonadotropic hypogonadism. While phenotypic expression can occasionally vary, heterozygous carriers generally possess adequate wild-type receptor activity to maintain normal reproductive physiology and fertility.
Population Frequency and Genetic Distribution
According to broad population databases such as gnomAD and ClinVar, rs121912529 is an ultra-rare variant globally. It is virtually absent from most international reference panels, with documented occurrences largely traced to specific founder effects in Northern European cohorts, particularly in Finland. Because pathogenic loss-of-function alleles in the FSHR gene are exceedingly uncommon, the vast majority of people carry two copies of the reference allele. Identifying a homozygote or compound heterozygote in general population screening is an extraordinary event, with the variant almost exclusively recognized through targeted diagnostic evaluation for primary ovarian insufficiency or hereditary hypogonadism.
Interpreting Results and Practical Next Steps
Encountering rs121912529 on a personal genetic report requires careful contextualization. Genetic testing platforms can occasionally produce false positives for ultra-rare variants; thus, any unexpected finding should be clinically validated via Sanger sequencing or an accredited clinical diagnostic panel. It is critical to recognize that carrier status (heterozygosity) does not equal a diagnosis of ovarian insufficiency or infertility. Genetic data alone should never be used to initiate, alter, or discontinue hormone replacement or fertility medications. Individuals with questions regarding their reproductive health, hormone profiles, or genetic carrier screening should review their results with a board-certified medical geneticist or reproductive endocrinologist.
How common is this variant?
The rs121912529 variant is an ultra-rare pathogenic allele across worldwide populations in gnomAD, observed primarily at very low frequencies in specific cohorts with Finnish ancestry due to a founder effect.
Frequently asked questions
What health conditions are associated with rs121912529?
Homozygous or compound heterozygous carriage of rs121912529 is associated with hypergonadotropic hypogonadism, primary ovarian insufficiency, and ovarian dysgenesis type 1. These conditions are characterized by poorly developed ovaries, absence of menses, and elevated pituitary hormone levels.
Does having one copy of this variant cause infertility?
Generally, no. Because FSHR-related ovarian dysgenesis follows an autosomal recessive pattern, heterozygous carriers retain one functional copy of the gene, which typically produces sufficient receptor activity for normal puberty and fertility.
How common is rs121912529 in the general population?
This variant is exceptionally rare globally, often classified as ultra-rare. While historically identified within Finnish pedigrees due to a genetic founder effect, it is seldom seen in broad multi-ancestry population databases.
Can medical treatments overcome an FSHR receptor defect?
Because the underlying receptor cannot properly respond to follicle-stimulating hormone, standard ovarian stimulation protocols using FSH are usually ineffective in affected homozygotes. Management typically focuses on hormone replacement therapy to support secondary sexual characteristics and bone density, guided by an endocrinologist.
Sources & further reading
Educational information only, last refreshed 9/6/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs121912529?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in FSHR
Functional polymorphism in the follicle-stimulating hormone receptor promoter modulating ovarian response and gonadotropin requirement during IVF stimulation.
FSHR Ser680Asn affects FSH receptor sensitivity; associated with ovarian response and PCOS risk.
This variant is associated with ovarian dysgenesis, which can impact secondary sexual characteristics and physical development.
This variant is linked to ovarian dysgenesis, potentially affecting hormonal regulation and physical appearance related to sexual maturation.
Common missense variant (Thr307Ala) in the follicle-stimulating hormone receptor gene that regulates ovarian response to gonadotropin stimulation during reproductive cycles.
FSHR intronic variant associated with ovarian response to follicle-stimulating hormone stimulation in assisted reproductive technology.